Chapter 18. Diagnosis and Management of Hereditary Bleeding Disorders: Including Congenital/Acquired Platelet Function Disorders
- Mark A. Crowther MD, MSc, FRCPC Professor Division Director3,4,
- Jeff Ginsberg MD, FRCPC Professor5,
- Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor6,7,
- Ralph M. Meyer MD, FRCPC Director Professor8,9,
- Richard Lottenberg MD, FACP Professor10
Published Online: 4 FEB 2009
DOI: 10.1002/9781444300857.ch18
Copyright © 2008 Blackwell Publishing Ltd
Book Title

Evidence-Based Hematology
Additional Information
How to Cite
Key, N. S. and Ma, A. D. (2009) Diagnosis and Management of Hereditary Bleeding Disorders: Including Congenital/Acquired Platelet Function Disorders, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch18
Editor Information
- 3
Division of Hematology, McMaster University, Hamilton, Ontario, Canada
- 4
St. Joseph's Hospital, Hamilton, Ontario, Canada
- 5
Department of Medicine, McMaster University, Hamilton, Canada
- 6
CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy
- 7
McMaster University, Hamilton, Canada
- 8
National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada
- 9
Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada
- 10
Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA
Publication History
- Published Online: 4 FEB 2009
- Published Print: 27 JUN 2008
ISBN Information
Print ISBN: 9781405157476
Online ISBN: 9781444300857
- Summary
- Chapter
Keywords:
- hereditary bleeding disorders;
- inherited disorders of hemostasis;
- von Willebrand disease (vWD) and inherited intrinsic platelet defects;
- PFA-100R closure times in congenital platelet disorders;
- PFA-100 in diagnostic evaluation of primary hemostasis disorders;
- hemarthrosis in hemophilia patients with high titer FVIII inhibitors;
- Randomized control trials (RCTs) of FVIII/FIX bypassing agents (PCC);
- acute hemarthrosis requiring bypassing therapy;
- rFVIIa and FEIBA - equivalent in hemostatic effect
Summary
This chapter contains sections titled:
Introduction
References
